Kornimate/medical-research-clean huggingface dataset:
spot drug-eluting stenting for long coronary stenoses

Conditions: Angioplasty

Summary: most doctors who use the new drug-eluting stents for the treatment of long coronary narrowings tend to cover the full length of the lesion with long or multiple stents. the investigators hypothesized that a policy of spot-stenting, i.e., stenting of only the very tight parts of the coronary narrowing, might result in better outcomes by means of avoiding multiple stents that have been associated with significant complications such as late stent thrombosis.

coronary artery lesion length is an independent predictor of restenosis following coronary intervention and the deployment of multiple or long bare metal stents has been associated with an increased risk of adverse clinical outcome. spot stenting, ie discrete stenting of only the most severe stenoses of long, diffuse lesions has been proposed as an alternative in this clinical setting. the introduction of drug-eluting stents has resulted in longer lesions being stented and the use of multiple, overlapping des in patients with diffusely diseased coronary arteries has been considered safe and effective. however, there has also been evidence of increased major adverse cardiac events (mace) with the use of multiple, overlapping des,10-12 while long des have been associated with increased probability of intraprocedural stent thrombosis.13 we hypothesized that an approach based on spot-stenting with the use of des might result in superior clinical outcomes compared to full cover of atheromatic lesions with long or multiple stents. we are therefore conducting a randomized comparison of spot versus multiple overlapping stenting on consecutive patients with long (\>20 mm) lesions and indications for percutaneous coronary intervention.

Eligibility criteria:
inclusion criteria: * consenting, consecutive patients with a de novo, native coronary artery lesion longer than 20 mm. exclusion criteria: * unprotected left main coronary artery stenosis, * left ventricular ejection fraction \<25%, or * contraindication to aspirin or clopidogrel
impact of prophylactic low-molecular weight heparin dosing on clotting parameters following cesarean delivery

Conditions: Thromboembolism; Postpartum DVT; Thrombosis

Summary: the aim of this study is to evaluate the efficacy of two dosing regimens of low molecular weight heparin (lmwh) to reach prophylactic anti-factor xa levels in post-cesarean delivery women. half of participants will receive a fixed dose of lmwh, while the other half will receive a weight-based dose. the hypothesis is that the use of a weight-based dose will result in more women reaching prophylactic levels.

venous thromboembolism (vte) is a major contributor to maternal morbidity and mortality. the immediate postpartum period is a high risk time for vte, and cesarean delivery is an additional risk factor. in the united states, use of postpartum vte prophylaxis with low-molecular weight heparin (lmwh) is commonly used but without a standard protocol or dose across all hospitals. a fixed-dose of lmwh is frequently used based on data from non-obstetric studies. however, there are concerns that in the postpartum population this fixed dose may not be adequate for prophylaxis. this study aims to evaluate the efficacy of fixed dose versus weight-based lmwh to reach prophylactic anti-xa levels in post-cesarean delivery women. this will be a randomized controlled trial (rct) with half of participants receiving a fixed dose of lmwh and half of participants receiving a weight-based dose of lmwh. the hypothesis is that the use of a weight-based lmwh compared to a fixed dose will result in more women achieving prophylactic anti-xa levels.

Eligibility criteria:
inclusion criteria: * cesarean delivery * meet facility guidelines for postpartum venous thromboembolism (vte) prophylaxis: presence of 1 major, or 2 or more moderate, risk factors. * major risk factors: history of venous thromboembolism, high risk thrombophilia, bmi ≥40, high risk medical comorbidities (heart disease, sickle cell disease, systemic lupus erythematosus, inflammatory bowel disease), cesarean hysterectomy, nephrotic range proteinuria, or cesarean intrapartum/during labor * moderate risk factors: bmi \> 30, multifetal pregnancy, postpartum hemorrhage (\>1l blood loss), tobacco use, non-laboring or elective cesarean, preeclampsia, infection, preterm delivery (\ 35 years, low risk thrombophilia, family history of venous thromboembolism, stillbirth, varicose veins, prolonged labor (\> 24 hours) exclusion criteria: * contraindication to anticoagulation * plan for therapeutic anticoagulation (antepartum or postpartum) * known renal dysfunction (creatinine clearance \< 30 ml/minute)

Keywords: factor xa biomarkers enoxaparin
intermittent fasting vs. high-intensity interval training on the lipid profile of obese individuals.

Conditions: Obesity

Summary: we aimed to ascertain the effect of intermittent fasting (if) vs. high-intensity interval training (hiit) on the lipid profile and waist circumference (wc) of obese individuals.

subjects and methods: this study included 40 obese individuals of both genders aged 35-50 years with an abnormal lipid profile. the patients were allocated at random to either group a or b, with both groups receiving medical treatment. group a followed the if regime, while group b performed hiit on the treadmill three times weekly, with an intervention duration of six weeks for both groups. body mass index (bmi), wc, levels of total cholesterol (tc), triglyceride (tg), low-density lipoprotein (ldl), high-density lipoprotein (hdl), alongside the framingham risk score (frs) were the evaluated variables.

Eligibility criteria:
inclusion criteria: inclusion criteria were as follows: (1) a bmi of 30 -40 kg/m2; (2) abnormal lipid profile, with a tc level \> 200 mg/dl, an ldl \> 100 mg/dl, a tc level \> 150 mg/dl, and an hdl \< 40 mg/dl; (3) steady vital signs, including blood pressure, respiration rate, and temperature at a baseline level. exclusion criteria: * the exclusion criteria included patients with the following medical conditions: cancer, unstable angina, uncontrolled cardiac rhythm, decompensated heart failure, persistent systolic blood pressure \> 200 mmhg, persistent diastolic blood pressure \> 120 mmhg, acute pericarditis or myocarditis, severe restrictive lung disease, chronic chest infection, severe obstructive lung disease, pregnant women, neurological disorders that affect balance and mentality (e.g., epilepsy), orthopedic or neurological problems that interfere with exercises, unstable endocrinal disorders, congenital or acquired lower limb deformity, kidney disease, infectious disease, immune disease, hearing impairment or mental disorder, uncontrolled t2dm.

Keywords: intermittent fasting,high-intensity training,,obesity
three-axis wearable adaptive vestibular stimulator

Conditions: Motion Sickness

Summary: the purpose of this study is to improve current galvanic vestibular stimulation (gvs) technology to ease the motion sickness often associated with virtual reality (vr) simulation.

the three-axis wearable adaptive vestibular stimulator (3waves) technology that combines galvanic vestibular stimulation (gvs) and virtual reality (vr) will not only increase vr-based simulation realism and presence, but will also mitigate the motion sickness often associated with vr simulation by re-coupling the vestibular and ocular inputs to the vr user. additionally, due to gvs technology's ability to accurately provide continuous inputs to the vestibular system, 3waves can intentionally simulate high-fidelity effects of spatial disorientation for training purposes.

Eligibility criteria:
inclusion criteria: * for our purposes, participants must be able to consent to participate themselves and be 21 to 55 years of age * must be able to attend in-person sessions at the mayo aerospace medicine and vestibular research laboratory in scottsdale, az. * no racial/ethnic groups will be excluded, although all participants must be fluent speakers of english. exclusion criteria: - history of vestibular disease, migraine, or significant balance disorder; history of severe motion sensitivity, women who are pregnant.
a study of tj003234 in rheumatoid arthritis patients

Conditions: Rheumatoid Arthritis

Summary: study purpose and design: a multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics of single ascending dose and multiple ascending doses of tj003234 in rheumatoid arthritis patients.


Eligibility criteria:
inclusion criteria: * subjects must be ≥ 18 and ≤70 years old when signing the informed consent, with no limitation of gender. * established rheumatoid arthritis patients, diagnosed by acr/eular criteria 2010 at least 6 months prior to randomisation. * single ascending dose: das28 score≤3.2. multiple ascending dose: das28 score≤5.1 and \>3.2. * allowed one or more standard treatments, but the start date should no later than 12 weeks(84 days) before the randomisation and should take at a stable dose more than 4 weeks(28 days) before the randomisation. the combination taken of methotrexate (mtx) and leflunomide was not allowed within 4 weeks (28 days) before randomization. * subjects must agree to attendance the study and signed the inform concent by themselves. * subjects(include subjects's wife) are no pregnancy plan during the sceering and 3 months after complete the study and agree to use contraceptives that protocol suggest. exclusion criteria: * employees of the hospital or any other person that paticipant in the study and their immedidte family members. * a documented history of an autoimmune disease other than ra (other than secondary sjögren's syndrome) . * previous received any biologic dmard therapy including tsdmard. •a positive hepatitis b (hbsag, anti-hbc, and/or igm anti-hbc), hepatitis c or hiv test at screening, indicative of a current or past infection. * a history of active tuberculosis (tb) or positive serological test for tb (quantiferon tb gold or t-spot). * female patients who are pregnant during the study, or are breastfeeding. •malignancy, or prior malignancy, with a disease free interval of \<5 years after diagnosis and intervention except curative treatment for basal and squamous cell skin cancer.

Keywords: rheumatoid arthritis biologics
continuous glucose monitoring following hospital discharge

Conditions: Type 2 Diabetes

Summary: in this 12-week prospective observational cohort study, hospitalized insulin-requiring patients with t2d will receive a dexcom continuous glucose monitor (cgm) to wear post-hospital discharge. patients will complete surveys assessing patient-reported outcomes prior to cgm use and following completion of the study. cgm data will be captured by the patient smartphone app and analyzed. patients will receive personalized cgm targets and alerts for hyperglycemia and hypoglycemia. customized reports/ decision support will be sent to the usual diabetes provider. the initial observational cohort study design will be followed by an extension phase of 12 weeks in which data on continuation of use and glucose control will be collected but no further reports will be communicated to providers.


Eligibility criteria:
inclusion criteria: * type 2 diabetes * basal insulin use \>10 units per day * hemoglobin a1c \>8.0% * smartphone compatible with clarity app * age ≥18 years exclusion criteria: * type 1 dm * inability to consent * pregnancy * prisoners * discharge to skilled nursing facility
protein supplementation impact on body muscle mass and fat mass in qataris post bariatric surgery, randomized controlled trials (rct)

Conditions: Obesity

Summary: one of the most common post-operative deficiencies or complications of bariatric surgery is protein malnutrition. it may lead to many predicaments such as malnutrition, vitamin, micro- and macronutrient deficiencies that can lead to deleterious consequences. a protein-rich diet make a person feel satiety and thereby the consumption will be low in overall energy intake. the objectives of our study are. the aim of this study is to assess the effect of protein supplementation on changes in health parameters such as fat mass, muscle mass, weigh change, protein (total and albumin), vit b12, zinc and magnesium, in qatari patients post bariatric surgery. our participants are qatari aged 18-45 years males and females recruited from the bariatric surgery centers of 2 major hmc hospitals (hgh hospital) and will be randomized to receive either the protein supplement (treatment group) or a dietary advice (control group). all participants will be equally followed and monitored for 3 months and data on the above parameters will be collected, together with other population characteristics, at baseline, 1 month and 3 month. data will then be analyzed using the most up-to-date spss statistical package to assess the effect of protein supplementation on the parameters of interest. statistical measures will be carefully chosen to properly assess the difference in the treatment (protein supplementation) effect compared with the control (dietary advice). investigators hypothesize that patients receiving protein supplement (intervention group) compared with patient not on protein supplement (placebo group) will maintain weight loss and other essential health parameters.


Eligibility criteria:
inclusion criteria: study participants must have the following criteria in order to participate in the trial: 1. qatari males or females. 2. aged between 18 and 60 year 3. based at the bariatric surgery list of hmc with their follow up scheduled be at hmc. exclusion criteria: patients will be excluded from participating in the trial if they have the following criteria: 1. any renal or liver disease because that will affect protein or albumin level in body. 2. past history of bariatric surgery 3. patients will be further excluded after starting the trial if they fall into the following categories: * subjects who did not take at least 80% of their intervention product amount per day, or * subjects who did not comply with the treatment (or placebo) for more than 3 days per week. also, patients who refuse to participate \& patients with baseline tests showing they are in need for protein supplements will be excluded from the study and given the needed protein supplements per the standard care.

Keywords: bariatric obesity protein supplements
efficacy and safety of pg-530742 in the treatment of mild to moderate knee osteoarthritis

Conditions: Osteoarthritis, Knee

Summary: matrix metalloproteinases (mmps) have been implicated in the cartilage degradation. pg-530742 inhibits some mmps, potentially limiting cartilage degradation and disease progression. this study will test the efficacy and safety of pg-530742 in the treatment of mild to moderate knee osteoarthritis.

matrix metalloproteinases have been implicated in the cartilage degradation that occurs in osteoarthritis. pg-530742 inhibits some of these matrix metalloproteinases, thus potentially limiting cartilage degradation and disease progression. this study will test the efficacy and safety of pg-530742 in the treatment of mild to moderate knee osteoarthritis.

Eligibility criteria:
inclusion criteria: * mild to moderate knee osteoarthritis confirmed by a radiographic technique. exclusion criteria: * secondary knee osteoarthritis; * diseases other than osteoarthritis that could cause knee pain; * any disease or intervention (surgery, intra-articular injection) that would have an impact on knee pain or mobility; * drugs that act potentially on the bone or cartilage component of the knee joint.

Keywords: primary disease: knee primary osteoarthritis
treating psychotic symptoms of young individuals presenting a first episode of schizophrenia: comparison of two state-of-the-art interventions

Conditions: Schizophrenia

Summary: to verify the efficacy of a group cognitive-behavioral therapy approach to lessening psychotic symptoms of individuals with a first episode of psychosis, and to compare its effects to a known skills training approach and a control group. our primary hypotheses were that cbt would do better than the control group at all points in time, and better than the skills training approach, though only at follow-ups

the study's protocol has the following objectives: to verify the efficacy of a group cbt approach; to compare the effects of cbt to those of the symptom management module and to a control group on psychotic symptoms and subjective experiences (e.g., depression, anxiety, self-esteem, social support, insight, and coping); and to assess what the effects are related to, via measuring client variables, therapist variables, and intervention variables that might explain the results. this study follows a randomized controlled trial design where participants are randomly assigned to one of the three groups at each recruiting wave. both treatment modalities hold the same number of group meetings as well as similar formats, lengths of treatment and operational structures, each operationalized in detailed manuals. interviewers are blind to group allocation. symptoms, both psychotic and otherwise, depression, self-esteem, social adaptation, anxiety, insight, social support, and coping are all measured before the beginning of treatment, three months follow-up, nine-months follow-up, and 15-months follow-up

Eligibility criteria:
inclusion criteria: 1) less than two years since their first consultation in psychiatry for psychotic symptoms, 2) a dsm-iv diagnosis in the schizophrenia spectrum (or a psychotic episode suggesting a non-mood related psychosis), 3) ability to read and write in english, 4) aged between 18 and 35, 5) no organic disorder, and 6) consenting to participate exclusion criteria: -

Keywords: cognitive-behavioral therapy symptom management first psychotic episode
multisensorial information's treatment in autism spectrum disorder

Conditions: Autism

Summary: introduction: autism spectrum disorder is characterized by deficits in three functional domains: language and communication, social reciprocity, and the presence of restricted interests/repetitive behaviors. there's also deficits in social cognition. when having a face-to-face conversation, a listener not only hears what a speaker is saying, but also sees the articulatory gestures that accompany those sounds. speech signals needs then a multisensory processing. impairments in multisensory perceptual binding may be particularly relevant in asd, given that hallmark features of the disorder include difficulties in speech, communication, and social interactions. objectives: the investigator suggest that atypical multisensory processing in asd may have an impact on speech perception and social processing. aims: methods: this pilot study measures free recall scores in 3 lists of words presentation after 30 minutes. in the first condition (ci) words are only listening. in the second condition (cii) words are associated with a picture of a mans face. in the third condition (ciii) words are associated with a video of a man speaking. three lists are homogeneous form words characteristics (lexical frequency, emotional valence norm, imageability). participants were 7- to 13-year-olds typically developing children (td) (n = 19) and asd children (n = 19). the investigator would create some new tools for exploring the treatment of a social information. these tools should be the closest of a ecological social interaction.


Eligibility criteria:
inclusion criteria: * boy or girl, * 7 - 13 years, * presenting a diagnosis dsm iv of disorder(confusion) of the autistic spectre: detected by the scale(ladder) adi ( autism diagnostic interview) or by teenagers (autism diagnostic observation schedule): typical autistic. these patients do not answer the diagnosis of psychosis according to kiddie-sads, * upper total iq or equal to 50, examination dating less than year before the inclusion, * french-speaking children, * signature of the informed consent by the parents(relatives) and the child, * membership to the social security. exclusion criteria: * genetic, neurological or neurosensory pathologies, * diagnosis of intrusive disorder(confusion) of the not specified development: ted our, * the patients will not be included who would participate in a program or a study of reeducation in the social fitnesses.
impact of maternal body weight on vitamin d status during pregnancy

Conditions: Obesity; Vitamin D Deficiency

Summary: research shows high levels of vitamin d deficiency in pregnant women in northern ireland. body composition is a determinant of vitamin d status. vitamin d is a fat soluble vitamin and therefore may be hidden within the adipose/fat tissue in overweight/obese individuals. all pregnant and breastfeeding women are advised to take a daily supplement containing 10μg vitamin d. the investigators hypothesise that overweight/ obese pregnant women have a lower vitamin d status than their leaner counterparts at the start of pregnancy and may need a higher daily supplementation to achieve a sufficient status. the investigators propose a randomised supplementation study where pregnant women (n 240) from the western health and social care trust area will be invited to take part. inclusion criteria: pregnant women first trimester, without current pregnancy related complications, singleton pregnancy, aged ≥18 years, with body mass index (bmi) \> 18.5kg /m². participants will be randomised to receive either 0μg (placebo) plus a multivitamin or 10μg vitamin d plus a multivitamin from 12 weeks gestation until delivery. the multivitamin already contains 10μg vitamin d; therefore participants will be randomised to receive a total of 10μg or 20μg vitamin d. blood samples (20mls) will be taken at 12, 28 and 36 weeks gestation. a sample of blood will be taken from the cord after delivery. vitamin d status is the main outcome measurement. all blood samples will be analysed for vitamin d and other associated metabolites. data will be collected on health and lifestyle, supplementation use and food intake. body composition measurements will be recorded at each appointment and infant anthropometric measurements will be taken from the maternal notes after delivery. findings from this research will be used to inform nutrition policy on appropriate vitamin d supplementation levels in pregnancy which may be dependent upon pre pregnancy bmi.


Eligibility criteria:
inclusion criteria: * pregnant women * age ≥18years * bmi \>18.5 kg/m² * without current pregnancy related complications * at least 12 weeks gestation * have a singleton pregnancy (as confirmed at first scan) * pregnant women who are currently taking vitamin d and have had a sun holiday will be included in this study. all participants will agree to discontinue any current supplementation and will be provided with a multivitamin for the duration of pregnancy. exclusion criteria: * aged \<18 years * pregnancy bmi \<18.5kg/m² * participants with multiple pregnancy * participants currently involved in another research study * participants with a history of gastrointestinal, hepatic, renal, vascular or haematological disorders. * participants who have had in vitro fertilisation (ivf) treatment * participants with a history of ntd affected pregnancies * pregnant women with active thyroid disease (e.g., graves, hashimoto or thyroiditis) * planned home births

Keywords: maternal body weight vitamin d pregnancy